Cognivia Releases New Patient Adherence Solution
Cognivia has announced the launch of its latest solution: Compl-AI©™.
Compl-AI is a predictive tool that helps clinical trial sponsors with patient recruitment and engagement strategies. The new tool scores patient behavior at screening using machine learning. The Compl-AI patient behavior score enables individualized patient engagement strategies. Beyond clinical research, Compl-AI offers healthcare providers an approach to tailor and adjust their patient support for better treatment adherence.
Using Compl-AI, sponsors can detect the risk of non-compliance and drop out risk before the start and monitor it over the course of their clinical trial.
Reference
Cognivia expands its portfolio of predictive solutions introducing Compl-AI©™, an innovative solution that predicts the risk of patient nonadherence & dropout. (2023, May 23). Cision PR Newswire.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
